Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > All Planned

<< Previous

Bullboard Posts

Next >>

Comment by Alex1726on Dec 18, 2020 9:08pm

213 Views

Post# 32145966

RE:All Planned

When the share price is going down they always come up with a news trying to increase or maintain the share price , this stock is going nowhere , they haven't met with the fda that was suposed to happen in november , any big pharma has shown any interest so far. They know they will have to finance the Phase III that is why they decided to reverse split 1 for 10 , only because they will need to issue more shares, it is the same story.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing